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Abstract
Background: Basaloid squamous cell carcinoma of the lung is a rare and highly malignant tumor mostly observed
in the proximal bronchi. Basaloid squamous cell carcinoma of the lung cases typically show rapid clinical
progression, very poor prognosis and special pathological morphology. This project aimed to examine the clinical
features of basaloid squamous cell carcinoma of the lung and the factors related to its prognosis; and to compare
survival outcomes between basaloid squamous cell carcinoma and poorly differentiated squamous cell carcinomas
(PDSC).
Methods: Between January 2004 and December 2008, pathological sections from basaloid squamous cell
carcinoma and PDSC of the lung were collected and retrospectively analyzed at Tianjin Medical University Cancer
Institute and Hospital. Data analysis was performed using Statistical Package for the Social Sciences (SPSS11.0). The
Kaplan-Meier method was used to calculate the survival rate. Log-rank test was used to compare the differences in
survival rate between the two groups. The factors influencing prognosis were analyzed using the Cox proportional
hazard model.
Results: A total of 120 pathological sections were used in the analysis of this study-22 from basaloid squamous
cell carcinoma cases and 98 from PDSC cases. Compared to the PDSC group, the basaloid squamous cell
carcinoma group had a larger proportion of female patients (p = 0.001); however it had higher proportion of male
smokers (p = 0.003). There were no statistically significant differences in survival rate between the two groups (c
2
= 1.200, p = 0.273). Additionally, prognosis of basaloid squamous cell carcinoma is significantly influenced by
treatment mode and clinical stages of the tumor. The post-operation mortality hazard of patients treated with a
combination chemotherapy and radiotherapy was 1.296 times higher than other treatment modes (p = 0.025).
Increases in post-operation mortality hazard ratio were also associated with more advanced clinical stage of tumors
(c
2 trend = 11.907, p = 0.000).
Conclusions: This study demonstrated that basaloid squamous cell carcinoma and PDSC have very similar clinical
features, and there are no significant differences in survival rates between the two groups. Hence, we conclude
that in the short term, the same clinical treatments and therapeutic modes can be administered to patients with
basaloid squamous cell carcinoma and PDSC of the lung.
Background
Basaloid carcinoma of the lung is a rare, highly malig-
nant and aggressive lung tumor with a high rate of
metastasis and death [1-3]. Basaloid carcinoma of the
lung was first described in a study conducted by
Brambilla in 1992, which analyzed the ultrastructural
features of basaloid carcinoma of the lung [4]. Of the 38
cases analyzed, basaloid carcinoma of the lung was pure
in 19 cases, and had a well-differentiated squamous cell
carcinoma component with intercellular bridging and
individual cell keratinization in 10 cases [4]. In 1999, the
World Health Organization (WHO) and International
Association for the Study of Lung Cancer (IASLC)
defined basaloid carcinoma as a variant of either squa-
mous cell carcinoma or large cell carcinoma [5].
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cally show rapid clinical progression, very poor prognosis
and special pathological morphology. So it has attracted
the attention of many scholars. Through retrospectively
analyzing cases of basaloid squamous cell carcinoma of
the lung and PDSC, this study examines the clinical fea-
tures of basaloid squamous cell carcinoma to determine
whether independent clinical treatment is needed.
Methods
Between January 2004 and December 2008, pathological
sections from basaloid squamous cell carcinoma and
PDSC of the lung were collected and retrospectively
analyzed at Tianjin Medical University Cancer Institute
and Hospital. Basaloid carcinoma diagnosis was based
on four criteria: (1) Invasive finger-like growth of a solid
lobular or anastomotic trabecular pattern from the
bronchial and/or glandular duct lining; (2) Small cuboi-
dal to fusiform cells with a mean diameter of 12-15 μm,
moderately hyperchromatic nuclei, and no prominent
nucleoli (there may be a scant nucleoli with visible cyto-
plasm and no nuclear molding); (3) Peripheral palisading
with radially arranged cells at the periphery of lobules;
and (4) A high rate of mitosis between 15-44 per 10
high-power fields [4]. Additionally, basaloid squamous
cell carcinoma of the lung pathological diagnosis was
based on the criteria defined by Brambilla et al.: squa-
mous cell differentiation or intercellular bridging and
individual cell keratinization can be seen within the
basal cell component, and the squamous cell component
takes up less than half of the basal cell component [4].
Clinical features including patient gender, age and
smoking history, clinical and pathological stage of the
tumor, treatment modalities, and survival status were
collected for each case. The clinical stage of tumors was
determined using the IASLC’s tumor, node, and metas-
tasis (TNM) classification for lung cancer (the 7
th edi-
tion). Survival time was measured from the date of
surgery to the last month of follow-up clinical exam/tel-
ephone call (April 2010 is the deadline) or death. Data
analysis was performed using Statistical Package for the
Social Sciences (SPSS11.0). Survival rates of the basaloid
squamous cell carcinoma and PDSC groups were calcu-
lated using the Kaplan-Meier method and differences in
the survival rates between the two groups were com-
pared using the Log-rank test. In addition, the factors
influencing prognosis were analyzed using the Cox pro-
portional hazard model. Hazard ratios and 95% confi-
dence intervals (95% CI) were calculated, and a p-value
of <0.05 was considered to be statistically significant.
Results
A total of 121 pathological sections were retrospectively
analyzed-19 from basaloid squamous cell carcinoma
cases and 102 from PDSC cases. One of the 19 basaloid
squamous cell carcinoma sections had a pure basaloid
pattern and was reclassified as a variant of a large cell
carcinoma. Additionally, of the 102 PDSC sections, four
sections displayed features that were in line with the
diagnostic criteria of basaloid squamous cell carcinoma
of the lung, and were reclassified as basaloid squamous
cell carcinoma. Consequently, a total of 120 pathological
sections are used in the analysis of this study-22 from
basaloid squamous cell carcinoma cases and 98 from
PDSC cases.
Clinical features of basaloid squamous cell carcinoma
and PDSC cases are summarized in Table 1. Compared
to the basaloid squamous cell carcinoma group, the
PDSC group had a significantly higher proportion of
male patients (p = 0.001). There was also a significant
difference in the proportion of male smokers between
the two groups (p = 0.003), but not in the proportion of
both male and female smokers (p = 0.513).
Among the basaloid squamous cell carcinoma cases,
all 22 follow ups were completed. Eleven deaths were
reported over an average follow up period of 22
months. Among the PDSC group, thirteen cases failed
to be followed up, 45 deaths were reported over an
average follow up period of 30 months-44 patients
died of lung cancer and 1 patient died of heart failure.
The median survival time of basaloid squamous cell
carcinoma and PDSC cases were 19 and 42 months
respectively. As shown in figure 1, there were no sig-
nificant differences in survival rates of patients in stage
I-IV between basaloid squamous cell carcinoma and
PDSC cases (c
2 =1 . 2 0 0 ,p = 0.273). Furthermore,
there were no significant differences in survival rates
of patients in stage I and II between the two groups,
a ss h o w ni nf i g u r e2 .
Lastly, it was found that the prognosis of patients was
significantly influenced by treatment mode and clinical
stage of the tumor. The post-operation mortality hazard
of patients treated with a combination of chemotherapy
and radiation therapy was 1.296 times higher than other
treatment modes (p = 0.025). In addition, the post-
operation mortality hazard of patients increased with
advanced clinical stage, which is summarized in Table 2
(c
2 trend = 11.907, p = 0.000). The post-operation mor-
tality hazard of patients in stage III and IV was 2.035
times greater than patients in stage I (p = 0.047). There
were no statistical differences in post-operation mortal-
ity hazard between patients in stage I and stage II
(hazard ratio 2.006, p = 0.069). Furthermore, no statisti-
cal associations were found between the prognosis of
patients and their age, gender, smoking status, history of
cardiovascular disease, pathological type (i.e. basaloid
squamous cell carcinoma or PDSC), and type of post-
operation treatment.
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PDSC
Variable basaloid squamous cell carcinoma (%) PDSC (%) p value
Sex (male/female) 14(63.6)/8(36.4) 91(92.9)/7(7.1) 0.001
Mean age (years) 58.6 60.5 0.363
Smoking history 18(81.8) 85(86.7) 0.513
Packs/year 26.3 20.8 0.103
Packs/year (male) 33.0 20.5 0.003
Cardiovascular history 6(27.3) 18(18.4) 0.516
Peri-operative death 0(0.0) 4(4.1) 1.000
Post-operative stages 0.101
I 9(40.9) 55(56.1)
II 8(36.4) 16(16.3)
III 4(18.2) 26(26.5)
IV 1(4.5) 1(1.0)
Operation types 0.487
Lobectomy 16(72.7) 67(68.4)
Segmentectomy 3(13.6) 8(8.2)
Pneumonectomy 3(13.6) 23(23.5)
Post-operative treatment 0.448
Chemotherapy 7(31.8) 33(33.7)
Radiation therapy 1(4.5) 7(7..1)
Combined 1(4.5) 15(15.3)
None 13(59.1) 43(43.9)
PDSC = poorly differentiated squamous cell carcinomas
Figure 1 The actual survival time of basaloid squamous cell carcinoma and PDSC patients in stage I-IV, p = 0.273
Wang et al. Journal of Cardiothoracic Surgery 2011, 6:10
http://www.cardiothoracicsurgery.org/content/6/1/10
Page 3 of 6Discussion
Basaloid squamous cell carcinoma of the lung as a var-
iant of squamous cell carcinoma is mostly observed in
the proximal bronchi. Most of the recent clinical
research studies have generally focused on conducting
survival analysis of basaloid carcinoma (BC) and poorly
differentiated squamous cell carcinomas (PDSC). More-
over, a study conducted by Moro-Sibilot et al. in 2008
examined the prognosis and difference in survival rates
between the variant of squamous cell carcinoma and
large cell carcinoma [6]. However, the clinical features
and prognosis of basaloid squamous cell carcinoma of
Figure 2 The actual survival time of basaloid squamous cell carcinoma and PDSC patients in stage I and stage II, p = 0.145
Table 2 The influence factors of post-operative survival Cox proportional hazard model analysis
Variable 95.0% CI used for Exp(B)
B SE Wald p value Hazard ratio low high
basaloid squamous cell carcinoma/PDSC -.486 .382 1.618 .203 .615 .291 1.301
age ≥ 70 .668 .375 3.173 .075 1.950 .935 4.064
sex .166 .517 .103 .748 1.181 .429 3.252
Smoking -.253 .367 .476 .490 .776 .378 1.593
Cardiovascular disease .408 .348 1.374 .241 1.503 .760 2.971
Operative type-Lobectomy 5.293 .071
Operative type-Segmentectomy -.562 .378 2.209 .137 .570 .272 1.196
Operative type-Pneumonectomy .440 .545 .653 .419 1.553 .534 4.519
Left/right lung .108 .315 .119 .730 1.115 .602 2.065
Clinical stage-stage I 4.837 .089
Clinical stage-stage II .696 .383 3.299 .069 2.006 .946 4.250
Clinical stage-stage III/IV .710 .358 3.929 .047 2.035 1.008 4.107
Combined therapy .831 .371 5.013 .025 2.296 1.109 4.751
CI = confidence intervals
PDSC = poorly differentiated squamous cell carcinoma
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gle-center and retrospective study examines and com-
pares the clinical features and prognosis of basaloid
squamous cell carcinoma with PDSC of the lung to
determine whether the former requires special clinical
treatment.
This study found that there were no significant differ-
ences between basaloid squamous cell carcinoma and
PDSC cases in the proportion of patients who smoked
(p = 0.513). This study also showed that the proportion
of male was significantly higher among the PDSC cases
(p = 0.001), and the proportion of male who smoke was
significantly higher among the basaloid squamous cell
carcinoma cases (p = 0.003). These findings differ from
other studies such as the one by Moro-Sibilot [6] which
showed that tobacco consumption was significantly
higher among BC patients compared to non-basaloid
carcinoma patients. Also, it was found that the age of
BC patients was older than non-basaloid carcinoma
patients (65.8 vs. 62.4, p = 0.03). In addition, a study
conducted by Kim et al. in 2003 concluded that there
were no significant differences in the clinical and biolo-
gical features of BC and PDSC patients in Yonsei Uni-
versity Hospital including age, gender, smoking history,
pulmonary function and the location of tumors [4].
The results of this study demonstrated that the median
survival time of basaloid squamous cell carcinoma and
PDSC patients were 19 months and 42 months respec-
tively-there was no significant difference in survival time
between the basaloid squamous cell carcinoma and PDSC
groups (c
2 = 1.200, p = 0.273). There were also no signifi-
cant differences in the survival rate of patients in stage I
and II between the two groups.T h e s ef i n d i n g ss u g g e s t
that the same therapeutic modes can be administered to
basaloid squamous cell carcinoma and PDSC patients.
In contrast to this study’s findings, a study conducted
by Moro et al. in 1994 showed that for patients in stage
I and II, there was a significant difference in the 5 year
survival rate between BC and PDSC groups-15% and
47% respectively, as well as the median survival time of
606 and 1218 days respectively (p = 0.009) [7]. However,
no significant differences in median survival time of
patients in stage III and IV were found between the two
g r o u p s[ 7 ] .K i me ta l ’s study found no significant differ-
ences between the prognosis of BC and PDSC groups
[8]. The 5-year survival rate of all patients between the
BC and PDSC groups was 36.5% and 40.6% (p = 0.86),
and median survival time was 34.4 months and 34.0
months respectively. The 5-year survival rate of patients
in stage I and II between the BC and PDSC groups was
53.9% and 57.7% (p = 0.97) respectively. Additionally,
there were no significant differences in relapse rate
between the two groups (p = 0.584). Further analysis
demonstrated that among patients in stage I, no lymph
node metastasis occurred, and there were no statistical
differences in the 5-year survival rate between BC and
PDSC groups-71.8% and 62.1% respectively, as well as
the median survival times of 79.6 months and 106.7
months respectively (p = 0.79).
T h ef i n d i n g so ft h i ss t u d ys h o w e dt h a tp r o g n o s i si s
significantly influenced by treatment mode and clinical
stage of the tumor. The post-operation mortality hazard
of patients treated with a combination of chemotherapy
and radiotherapy was 1.296 times higher than other
treatment modes (p = 0.025). The post-operation mor-
tality hazard of patients in stage III and IV was 2.035
times higher than patients in stage I (p = 0.047). Addi-
tionally, there was no significant difference in post-
operation mortality hazard between patients in stage I
and stage II (hazard ratio = 2.006, p = 0.069). These
results differ slightly from other research such as Kim et
al.’s study, which revealed that age (60 years old, hazard
ratio = 2.179, p = 0.000) and an advanced clinical stage
(stage III, hazard ratio = 2.264, p = 0.000) significantly
influenced BC prognosis [7]. Additionally, Coppola et al.
found that prognosis was related to the proportion of
basal cells in tumors-higher basal cell counts were asso-
ciated with poor prognosis [1]. Also, Moro et al.’ss t u d y
demonstrated that operative type (i.e. pneumonectomy,
lobectomy, segmentectomy) has no bearing on the prog-
nosis of BC and PDSC patients [8].
Differences between the findings in this study and
other research may be due to variations in the source of
case subjects, treatment modalities, environmental fac-
tors and research design. For example, retrospective
analysis was conducted in this study; however, most of
the other studies did not conduct retrospective analysis.
Additionally, analyses on prognosis and factors influen-
cing prognosis were based on basaloid squamous cell
carcinoma patients, in contrast, most of the other stu-
dies based their analyses on patients with BC or large
cell carcinoma.
Conclusions
Although there is a low incidence of basaloid squamous
cell carcinoma of the lung, it remains a high degree
malignancy tumor that is difficult to diagnose before
surgery. In addition, there is no agreed upon treatment
for patients with basaloid squamous cell carcinoma.
This study demonstrated that basaloid squamous cell
carcinoma and PDSC have very similar clinical features,
and there are no significant differences in survival rates
between the two groups. Hence, we conclude that in the
short term, the same clinical treatments and therapeutic
modes can be administered to patients with basaloid
squamous cell carcinoma and PDSC of the lung. Further
research on a larger scale needs to be conducted to con-
firm this conclusion in the long run.
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